Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Vyant Bio Inc (VYNT)

Vyant Bio Inc (VYNT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 85,509
  • Shares Outstanding, K 28,986
  • Annual Sales, $ 5,750 K
  • Annual Income, $ -8,000 K
  • 60-Month Beta 2.43
  • Price/Sales 14.87
  • Price/Cash Flow N/A
  • Price/Book 1.35
Trade VYNT with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.82 +4.61%
on 07/27/21
3.88 -23.99%
on 07/02/21
-0.79 (-21.12%)
since 06/30/21
3-Month
2.78 +6.12%
on 05/11/21
4.24 -30.34%
on 06/07/21
-0.63 (-17.60%)
since 04/30/21
52-Week
2.11 +39.97%
on 10/30/20
17.50 -83.14%
on 02/10/21
+0.01 (+0.43%)
since 07/30/20

Most Recent Stories

More News
Vyant Bio to Present at A.G.P.'s Virtual MedTech Summer Conference

Vyant Bio, Inc. ("Vyant Bio", "Company") (Nasdaq: VYNT), an emerging leader in novel drug discovery, is pleased to announce that Jay Roberts, Chief Executive Officer, will present at A.G.P.'s Virtual MedTech...

VYNT : 2.95 (unch)
Vyant Bio Announces Issuance of Key Patent for High-Throughput Optical Assay of Human Mixed Cell Population Spheroids

Vyant Bio, Inc. ("Vyant Bio", the "Company") (Nasdaq: VYNT), an emerging leader in novel drug discovery technologies, announced today that its wholly-owned subsidiary, StemoniX, Inc. ("StemoniX"), was...

VYNT : 2.95 (unch)
Vyant Bio Inc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 18, 2021 / Vyant Bio Inc (NASDAQ:VYNT) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 18, 2021 at 8:30 AM Eastern...

VYNT : 2.95 (unch)
Vyant Bio Reports First Quarter 2021 Results and Provides Strategic Business Update

Vyant Bio, Inc. (the "Company") (Nasdaq: VYNT), is an innovative biotechnology company focused on partnering with pharmaceutical and other biotechnology companies to identify novel and repurposed therapeutics...

VYNT : 2.95 (unch)
Vyant Bio Announces Investor Conference Call and Webcast for First Quarter 2021

Vyant Bio, Inc. ("Vyant Bio", "Company") (Nasdaq: VYNT), is focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of preclinical...

VYNT : 2.95 (unch)
Vyant Bio to Present at BioNJ's 11th Annual BioPartnering Conference

Vyant Bio, Inc. ("Vyant Bio", "Company") (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery...

VYNT : 2.95 (unch)
Vyant Bio, Inc., Ordaōs Bio, and Cellaria, Inc. Announce Collaboration to Design and Qualify Biomarker-Specific Small Protein Therapeutics

New collaboration mitigates risk in drug discovery process with artificial intelligence and in vitro "avatar" clinical trials

VYNT : 2.95 (unch)
Vyant Bio Announces Newly Appointed Board of Directors

Vyant Bio, Inc. (the "Company") (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery of...

VYNT : 2.95 (unch)
KYMR : 60.18 (+4.84%)
NANO : 35.33 (-0.81%)
LQDA : 2.30 (-3.77%)
IDRA : 1.0300 (-1.90%)
SNDX : 14.58 (-1.29%)
Vyant Bio Announces Investor Webcast to Provide Updates Post Merger between Cancer Genetics and StemoniX

Vyant Bio, Inc. (the "Company") (Nasdaq: VYNT), is a new force in drug discovery focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery and...

CGIX : 4.61 (-2.33%)
VYNT : 2.95 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

VYANT BIO INC. operates through wholly-owned subsidiaries, StemoniX and vivoPharm. StemoniX is empowering the discovery of new medicines through the convergence of novel human biology and software technologies. vivoPharm offers proprietary preclinical test systems supporting clinical diagnostic offerings...

See More

Key Turning Points

3rd Resistance Point 3.15
2nd Resistance Point 3.10
1st Resistance Point 3.02
Last Price 2.95
1st Support Level 2.89
2nd Support Level 2.84
3rd Support Level 2.76

See More

52-Week High 17.50
Fibonacci 61.8% 11.62
Fibonacci 50% 9.80
Fibonacci 38.2% 7.99
Last Price 2.95
52-Week Low 2.11

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar